GlassScriptPhysician profile
Ellen R Goldmark
NPI 1720247703
$5,538.42
in general payments reported to CMS, 2019-2025
37 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $235 · 2021: $574 · 2022: $430 · 2023: $856 · 2024: $1,132 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,954 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,953.93 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $971.98 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $869.11 | 2019-2020 | |
| Abbvie INC. | $511.30 | 2021-2025 | |
| Astellas Pharma US INC | $359.03 | 2019-2023 | Myrbetriq |
| Axonics, INC. | $348.41 | 2022-2024 | Axonics |
| Boston Scientific Corporation | $220.45 | 2019-2025 | Solyx Sis System, Axonics, Upsylon |
| Myriad Genetic Laboratories, INC. | $208.13 | 2021-2025 | Prolaris |
| Allergan, INC. | $195.25 | 2019-2021 | |
| Janssen Biotech, INC. | $159.39 | 2019-2025 | Erleada, Akeega |
| Urogen Pharma, INC. | $138.33 | 2021-2025 | Jelmyto |
| Immunitybio, INC. | $135.17 | 2025 | |
| Medtronic, INC. | $134.77 | 2023-2024 | Interstim |
| Progenics Pharmaceuticals, INC. | $113.77 | 2024 | |
| Coloplast Corp | $104.59 | 2021-2025 | Porges Coloplast, Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $101.56 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $89.46 | 2022-2025 | |
| Amgen INC. | $83.30 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $81.17 | 2023-2024 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $67.68 | 2019-2023 | Provenge |
| Endo Pharmaceuticals INC. | $66.67 | 2020-2023 | Aveed, Edex, Xiaflex |
| Pfizer INC. | $63.03 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $60.75 | 2019-2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals LP | $58.22 | 2022-2025 | Imfinzi |
| Antares Pharma, INC. | $53.36 | 2019-2022 | |
| Urovant Sciences INC | $48.09 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $45.97 | 2021-2022 | |
| Tolmar, INC. | $34.30 | 2025 | Eligard, Jatenzo |
| Endo USA, INC. | $28.28 | 2024 | Edex, Aveed, Xiaflex |
| Bluewind Medical | $25.18 | 2025 | Revi |
| Blue Earth Diagnostics | $24.60 | 2022 | |
| Civco Medical Instruments | $24.15 | 2025 | |
| Abc Home Medical Supply, INC. | $23.29 | 2025 | |
| Accord Healthcare, INC. | $22.88 | 2024 | |
| Valencia Technologies Corporation | $17.92 | 2025 | Ecoin Device Kit |
| Telix Pharmaceuticals | $16.78 | 2024 | Illuccix |
| Olympus America INC. | $16.38 | 2020 | |
| Merck Sharp & Dohme LLC | $15.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Goldmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.